OM:SOBIBiotechs
Assessing Swedish Orphan Biovitrum (OM:SOBI) Valuation After Aspaveli Approval For Rare Kidney Diseases In Europe
Swedish Orphan Biovitrum (OM:SOBI) is back in focus after the European Commission approved Aspaveli for certain rare kidney diseases in adults and adolescents, a decision based on results from the Phase 3 VALIANT study.
See our latest analysis for Swedish Orphan Biovitrum.
The Aspaveli approval seems to have coincided with a pick up in momentum, with a 1-day share price return of 2.76% contributing to a 7-day gain of 4.26% and a 90-day share price return of 5.35%. The 3-year total shareholder...